French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Monday announced positive results from the Phase 2 CoTikiS study of Lusvertikimab (OSE-127), an anti-IL7R monoclonal antibody, for the treatment of ulcerative colitis (UC).
Lusvertikimab met the primary endpoint, demonstrating significant improvement in the Modified Mayo Score at both doses tested. The drug also showed positive results on key secondary endpoints, including clinical and endoscopic remission.
The drug was well-tolerated with a favourable safety profile during both the induction and extension periods.
These results position Lusvertikimab as a potential first-in-class interleukin-7 antagonist for the treatment of autoimmune and inflammatory diseases.
Renalys Pharma secures Orphan Drug Designation in Japan for sparsentan
Minghui Pharmaceutical reports phase III success for MH004 ointment in atopic dermatitis
CBC Group acquires UCB's mature neurology and allergy business in China
MGI Tech collaborates with Universidad de San Martin de Porres
Allink Biotherapeutics completes USD42m Series A financing round
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children
GSK secures EU approval for fully liquid Menveo vaccine
Oxford Nanopore and UK Biobank partner to create world's largest epigenetic dataset
Novartis' Kisqali approved in EU for broader population of high-risk early breast cancer patients
Faron Pharmaceuticals reports positive interim Phase 2 BEXMAB trial results
MaxScientific signs licensing deal with Seragon Biosciences
PTC Therapeutics reports utreloxastat trial in ALS patients failed to meet efficacy endpoints